AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 202 min read$ISRG

Intuitive Surgical, Inc. (ISRG) Q3 Revenue Rises 22% to $3.05B

Intuitive Surgical reported Q3 2026 revenue of $3.05B, up 22% YoY, driven by procedure growth and system placements. GAAP EPS declined due to a $450M antitrust settlement charge, while non-GAAP EPS rose to $3.00. The company cited procedure-led growth and expanding installed base as key factors.

Original reporting
tradingview.com
Published Oct 20, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Intuitive Surgical, Inc. (ISRG) Q3 Revenue Rises 22% to $3.05B — source image
Source · tradingview.com
Decision brief

The 30-second read

$ISRGNeutralHigh
01

Why it matters

The earnings release provides fresh data on revenue growth and a material expense, offering traders a basis for short‑term positioning.

02

Market read

First report of Q3 results for a large‑cap medical device company; material numbers affect stock valuation.

03

What to watch

Potential cost synergies from the settlement and long-term growth from expanding installed base.

Relevance 8/10Novelty 8/10Timing: after-hours release

Background

Intuitive Surgical released its Q3 2026 earnings, reporting a significant revenue increase and a large antitrust settlement charge.

Company-level read

Ticker impact

$ISRGNeutralHigh confidence
Context

Q3 2026 revenue rose 22% to $3.05B; GAAP EPS fell due to a $450M antitrust settlement charge.

Expected impact

mixed pressure as the market weighs strong revenue growth against the large settlement charge.

Evidence & confidence

Revenue growth is a positive catalyst, but the $450M charge could offset earnings upside, likely leading to modest downside or flat reaction.

Market effects

Sector

Highlights continued demand for robotic surgery systems, supporting the medical device sector.

Regional

U.S. healthcare stocks may see modest movement as investors digest the settlement impact.

Global

Limited to firms with similar surgical robotics exposure.

Counterpoint

What could challenge this read

The settlement charge may be a one-time hit; future quarters could see stronger earnings momentum.

Key entities

  • company
    Intuitive Surgical, Inc.

    Manufacturer of the da Vinci surgical system.

Read at source← All news

StoryIntuitive Surgical posts Q3 2026 results with revenue up 22% and a $450 million antitrust settlement charge

Also covered by

5 outlets

Related articles

OCT 20
$ISRGMedAI 8/10

Intuitive Surgical, Inc (ISRG) Q3 2026 Earnings Call Transcript

Intuitive Surgical (ISRG) reported Q3 2026 earnings, highlighting 15% total procedure growth, with 14% in da Vinci and 31% in Ion procedures. U.S. da Vinci growth was 10%, while international growth was 20%. The company installed over 13,200 da Vinci and Ion systems worldwide. Revenue growth was driven by strong demand for da Vinci 5 and SP platforms, with 28% increase in system placements. The company also announced plans for a new manufacturing facility in Malaysia.

news.alphastreet.com3 min
OCT 20
$ISRGMedAI 8/10

Intuitive Surgical (ISRG) Q3 Earnings Beat Expectations with Str

Intuitive Surgical (ISRG) reported Q3 earnings that surpassed expectations, with revenue of $3.05B, up 21.5% YoY, and EPS of $3.00. The company saw a 15% rise in procedures and placed 546 new da Vinci systems. ISRG's GF Value suggests it is undervalued by 31.1%, with a GF Score of 96/100. Insiders sold $93.4M in shares, while gurus show mixed activity.

gurufocus.com2 min